Liquid biopsy, a noninvasive approach to the detection and analysis of tumor components such as DNA in blood, has the potential to allow detection of cancer, measurement of tumor mutation burden, and identification of drug resistance mechanisms.13 Indeed, it was recently approved as an alternative to rebiopsy for detection of the T790M mutation of EGFR. This evidence concerns the gene EGFR and neoplasm.